New hope for tough pancreatic cancer: targeted drug enters major trial
NCT ID NCT07232875
Summary
This major study is testing if adding a new drug called HRS-4642 to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). About 588 participants will be randomly assigned to receive either the new combination or the standard treatment. The main goals are to see if the new combination helps patients live longer without their cancer getting worse and helps them live longer overall.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D-MUTANT ADVANCED OR METASTATIC PANCREATIC CANCER IN THE FIRST-LINE SETTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Contact
Conditions
Explore the condition pages connected to this study.